Europe Rare Hemophilia Factors Market Size & Outlook

The rare hemophilia factors market in Europe is expected to reach a projected revenue of US$ 139.8 million by 2030. A compound annual growth rate of 6.7% is expected of Europe rare hemophilia factors market from 2024 to 2030.
Revenue, 2023 (US$M)
$88.8
Forecast, 2030 (US$M)
$139.8
CAGR, 2024 - 2030
6.7%
Report Coverage
Europe

Europe rare hemophilia factors market, 2018-2030 (US$M)

Europe

Europe rare hemophilia factors market highlights

  • The Europe rare hemophilia factors market generated a revenue of USD 88.8 million in 2023.
  • The market is expected to grow at a CAGR of 6.7% from 2024 to 2030.
  • In terms of segment, factor i was the largest revenue generating product in 2023.
  • Factor I is the most lucrative product segment registering the fastest growth during the forecast period.


Europe data book summary

Market revenue in 2023USD 88.8 million
Market revenue in 2030USD 139.8 million
Growth rate6.7% (CAGR from 2023 to 2030)
Largest segmentFactor i
Fastest growing segmentFactor I
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationFactor I
Key market players worldwideNovo Nordisk A/S ADR, Biogen Inc, Bayer AG, Pfizer Inc, Takeda Pharmaceutical Co Ltd, Baxalta, CSL Ltd, Bio Products Laboratory


Other key industry trends

  • In terms of revenue, Europe region accounted for 28.4% of the global rare hemophilia factors market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 105.5 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Rare Hemophilia Factors Market Scope

Rare hemophilia factors market segmentation & scope
Factor I
Factor II
Factor V
Factor VII
Factor X
Factor XI
Factor XIII
Drug Type
Factor Concentrates
Fresh Frozen Plasma
Cryoprecipitate
Others
Countries
U.S.
Canada
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Japan
China
India
Australia
South Korea
Thailand
Mexico
Brazil
South Africa
Saudi Arabia
UK
Argentina
UAE
Kuwait

Rare Hemophilia Factors Market Companies

Name Profile # Employees HQ Website

Europe rare hemophilia factors market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare hemophilia factors market will help companies and investors design strategic landscapes.


Factor i was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Europe rare hemophilia factors market based on factor i covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Europe rare hemophilia factors market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Europe rare hemophilia factors market databook

  • Our clientele includes a mix of rare hemophilia factors market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe rare hemophilia factors market , including forecasts for subscribers. This continent databook contains high-level insights into Europe rare hemophilia factors market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Europe rare hemophilia factors market

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more